ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966.
   PubMed Web of Science ®Google Scholar
• Zaki AM, Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–821.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443.
   PubMed Web of Science ®Google Scholar
• Team CCR. SARS-CoV-2 B.1.1.529 (Omicron) variant -- United States, December 1–8, 2021. Morb Mortal Wkly Rep. 2021;70(50):1731–1734.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, van der Zee R, de Haan CAM, et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):eabb2507.
   Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):1–6.
   Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
   PubMed Web of Science ®Google Scholar
• Fung TS, Liu DX. Similarities and dissimilarities of COVID-19 and other Coronavirus diseases. Annu Rev Microbiol. 2021;75(1):1–29.
   PubMed Web of Science ®Google Scholar
• Chan KK, Dorosky D, Sharma P, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369(6508):1261–1265.
   PubMed Web of Science ®Google Scholar
• Glasgow A, Glasgow J, Limonta D, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci. 2020;117(45):28046–28055.
   PubMed Web of Science ®Google Scholar
• Higuchi Y, Suzuki T, Arimori T, et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021;12(1):3802.
   PubMed Web of Science ®Google Scholar
• Ballou CE. Isolation, characterization, and properties of Saccharomyces cerevisiae MNN mutants with nonconditional protein glycosylation defects. Meth Enzymol. 1990;185:440–470.
   PubMed Web of Science ®Google Scholar
• Chung CY, Majewska NI, Wang Q, et al. SnapShot: N-Glycosylation processing pathways across kingdoms. Cell. 2017;171(1):258–258.e1.
   PubMed Web of Science ®Google Scholar
• Joshi HJ, Narimatsu Y, Schjoldager KT, et al. SnapShot: O-Glycosylation pathways across kingdoms. Cell. 2018;172(3):632–632.e2.
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Hasan M, Ahmed A. Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. Rev Med Virol. 2021;31: 10.1002/rmv.2213.
   Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme clonging and functional expression as a captopril-insensitive carboxypeptidase*. J Biol Chem. 2000;275(43):33238–33243.
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4(10):1015–1028.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367(43):1444–1448.
   PubMed Web of Science ®Google Scholar
• Zhao P, Praissman JL, Grant OC, et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe. 2020;28(4):586–601.e6.
   PubMed Web of Science ®Google Scholar
• Barros EP, Casalino L, Gaieb Z, et al. The flexibility of ACE2 in the context of SARS-CoV-2 infection. Biophys J. 2021;120(6):1072–1084.
   PubMed Web of Science ®Google Scholar
• Acharya A, Lynch DL, Pavlova A, et al. ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV. Chem Commun. 2021;57(48):5949–5952.
   PubMed Web of Science ®Google Scholar
• Mehdipour AR, Hummer G. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc Natl Acad Sci. 2021;118(19):e2100425118.
   PubMed Web of Science ®Google Scholar
• Zhai X, Sun J, Yan Z, et al. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. J Virol. 2020;94:e00831–20
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699–3715.
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Zhang L, et al. Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discov. 2021;7(1):21.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020, Jun;369(6506):1014–1018.
   PubMed Web of Science ®Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.. New Engl J Medicine. 2021;385:NEJMoa2102685.
   PubMed Web of Science ®Google Scholar
• Rujas E, Kucharska I, Tan YZ, et al. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. Nat Commun. 2021;12(1):3661.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu W, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020;3(3):tbaa020.
   Google Scholar
• Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–295.
   PubMed Web of Science ®Google Scholar
• Dong J, Zost SJ, Greaney AJ, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiol. 2021;6(10):1233–1244.
   PubMed Web of Science ®Google Scholar
• Collier DA, Marco AD, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–141.
   PubMed Web of Science ®Google Scholar
• Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220–4236.e13.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675.
   PubMed Web of Science ®Google Scholar
• Hutchison C, Phillips S, Edgell M, et al. Mutagenesis at a specific position in a DNA sequence. J Biol Chem. 1978;253(18):6551–6560.
   PubMed Web of Science ®Google Scholar
• Shortle D, Nathans D. Local mutagenesis: a method for generating viral mutants with base substitutions in preselected regions of the viral genome. Proc Natl Acad Sci. 1978;75(5):2170–2174.
   PubMed Web of Science ®Google Scholar
• Krumpe LR, Schumacher KM, McMahon JB, et al. Trinucleotide cassettes increase diversity of T7 phage-displayed peptide library. BMC Biotechnol. 2007;7(1):65.
   PubMed Web of Science ®Google Scholar
• Baronio R, Danziger SA, Hall LV, et al. All-codon scanning identifies p53 cancer rescue mutations. Nucleic Acids Res. 2010;38(20):7079–7088.
   PubMed Web of Science ®Google Scholar
• Tang L, Gao H, Zhu X, et al. Construction of small-intelligent focused mutagenesis libraries using well-designed combinatorial degenerate primers. BioTechniques. 2012;52(3):149–158.
   PubMed Web of Science ®Google Scholar
• Kille S, Acevedo-Rocha CG, Parra LP, et al. Reducing codon redundancy and screening effort of combinatorial protein libraries created by saturation mutagenesis. ACS Synth Biol. 2013;2(2):83–92.
   PubMed Web of Science ®Google Scholar
• Ashraf M, Frigotto L, Smith ME, et al. ProxiMAX randomization: a new technology for non-degenerate saturation mutagenesis of contiguous codons. Biochem Soc Trans. 2013;41(Pt 5):1189–1194.
   PubMed Web of Science ®Google Scholar
• Kitzman JO, Starita LM, Lo RS, et al. Massively parallel single-amino-acid mutagenesis. Nat Methods. 2015;12(3):203–206.
   PubMed Web of Science ®Google Scholar
• Sims JJ, Greig JA, Michalson KT, et al. Intranasal gene therapy to prevent infection by SARS-CoV-2 variants. PLoS Pathog. 2021;17(7):e1009544.
   PubMed Web of Science ®Google Scholar
• Baden LR, Sahly HME, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med. 2020;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2(10):e594–e602.
   PubMedGoogle Scholar
• Zoufaly A, Poglitsch M, Aberle JH, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8(11):1154–1158.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224.
   PubMed Web of Science ®Google Scholar